Financial results - NICOMEDICA SRL

Financial Summary - Nicomedica Srl
Unique identification code: 14443237
Registration number: J26/86/2002
Nace: 8622
Sales - Ron
206.821
Net Profit - Ron
70.365
Employee
5
The most important financial indicators for the company Nicomedica Srl - Unique Identification Number 14443237: sales in 2023 was 206.821 euro, registering a net profit of 70.365 euro and having an average number of 5 employees. Firma isi desfasoara activitatea in domeniul Activitati de asistenta medicala specializata having the NACE code 8622.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Nicomedica Srl

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR 29.606 66.855 97.577 116.164 118.814 138.831 74.463 80.108 199.621 206.821
Total Income - EUR 35.796 71.537 103.755 126.978 129.575 148.450 83.819 132.841 200.329 206.821
Total Expenses - EUR 33.671 59.522 86.956 96.094 105.197 94.374 66.968 71.183 141.894 134.430
Gross Profit/Loss - EUR 2.126 12.015 16.799 30.885 24.378 54.076 16.852 61.658 58.435 72.391
Net Profit/Loss - EUR 1.242 9.920 15.823 29.723 23.190 52.688 16.119 60.716 56.485 70.365
Employees 1 3 4 5 5 5 2 2 3 5
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded. In the last year of activity, the sales increased by 3.9%, from 199.621 euro in the year 2022, to 206.821 euro in 2023. The Net Profit increased by 14.051 euro, from 56.485 euro in 2022, to 70.365 in the last year.

Check the financial reports for the company - Nicomedica Srl

Rating financiar

Financial Rating -
Nicomedica Srl

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Nicomedica Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Nicomedica Srl

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Nicomedica Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Nicomedica Srl - CUI 14443237

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets 54.990 102.097 148.813 237.093 233.810 197.078 191.185 161.100 169.091 128.513
Current Assets 50.615 30.687 29.006 14.733 25.510 6.958 24.313 71.980 17.038 40.958
Inventories 0 0 0 0 0 0 0 0 0 0
Receivables 127 109 18.365 52 116 0 0 0 852 834
Cash 50.488 30.578 10.641 14.682 25.394 6.958 24.313 71.980 16.186 40.125
Shareholders Funds 85.199 95.829 63.797 92.441 113.934 164.416 177.417 229.819 176.301 161.307
Social Capital 0 45 45 44 43 42 41 40 41 40
Debts 607 17.072 114.021 126.328 122.523 26.603 34.534 3.261 9.828 8.164
Income in Advance 24.361 19.883 43.563 33.058 22.863 13.017 3.546 0 0 0
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "8622 - 8622"
CAEN Financial Year 8622
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 40.958 euro in 2023 which includes Inventories of 0 euro, Receivables of 834 euro and cash availability of 40.125 euro.
The company's Equity was valued at 161.307 euro, while total Liabilities amounted to 8.164 euro. Equity decreased by -14.459 euro, from 176.301 euro in 2022, to 161.307 in 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Nicomedica Srl

Comments - Nicomedica Srl

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.